Strategic Intent: Boehringer Ingelheim's Brian Hilberdink on Launching Into the GLP-1 Era

Brian Hilberdink, President of US Human Pharma at Boehringer Ingelheim, joined Strategic Intent to talk about leading one of the company's most ambitious US launch periods in years, spanning a specialty drug in interstitial lung disease, an established franchise in cardiometabolic disease and a potential entry into the hyper-competitive obesity market. He discusses how private ownership shapes long-term decision-making, why he wants to reframe the obesity conversation away from the scale and toward metabolic health, how the payer landscape has fundamentally changed since he started in the industry, and what role AI will play in the future of commercialization.